1. **Members**
Refer to Appendix A: List of Members and Observers.

2. **Introduction**
The Commercialization and Legacy Committee reviews GlycoNet knowledge and technology exchange and exploitation (KTEE) opportunities, plans, programs and initiatives. It provides strategic advice and funding recommendation to the Board of Directors, and provides mentorship to Network investigators to support the identification, development, protection, commercialization and financing of intellectual property (IP) arising from Network research. The Committee will also guide GlycoNet in developing and implementing its legacy plan.

While GlycoNet may not always be a direct agent of commercialization itself, GlycoNet will be fully supporting our network researchers, their associated Technology Transfer Offices, and commercial partners in assembling the necessary ingredients for commercial success.

3. **Authority**
The Commercialization and Legacy Committee is constituted pursuant to a decision of the Board of Directors on October 27, 2015.

4. **Membership**
The GlycoNet Commercialization and Legacy Committee shall be comprised of:
- A minimum of four (4) and a maximum of eight (8) members;
- A Chair of the Commercialization and Legacy Committee who shall be a Director but shall not be the Chair of the Board or the Scientific Director;
- At least two (2) members with industrial and executive experience; and
- At least one (1) member with IP protection or legal or regulatory expertise;

5. **Term**
Members shall normally be appointed for a term of two (2) years, renewable.

6. **Role**
The main function of the Committee shall be to act as an enabling capacity to the GlycoNet Board of Directors with respect to the Network’s Partnering, IP, Commercialization, and Legacy Strategies, and specifically do the following:
- Review the Network’s partnering, IP and commercialization strategies on an ongoing basis, make recommendations to the Board as appropriate on how to move forward, and assume any specific roles as may be delegated to it by the Board from time to time.
- Recommend funding for patent filing of Network selected IP.
- Recommend funding for Translational Projects that could add value to Network protected IP.
- Recommend funding for Strategic Initiatives that could increase partnerships and translational research.
- Assist the Network management team and institutional stakeholders to develop and implement effective commercialization approaches through:
  - Providing guidance on how best to review and assess GlycoNet IP for potential commercial value.
Making recommendations on appropriate commercialization avenues, if any.

- Providing guidance on identifying and accessing sources of financing and/or partnerships (including industry and not-for-profit) to advance the IP.
- Participating in identification and selection of commercialization personnel to support the Network’s strategy as may be appropriate.
- Providing advice and support in garnering external support for the recommended courses of action.

- Assist the Network management team to plan and implement legacy strategies by:
  - Suggesting various models for GlycoNet legacy
  - Identifying potential sources of revenue and partners

7. Meetings

The Commercialization and Legacy Committee does not require compliance to pre-set statutory meetings, but will meet at the request of the Chair or a member of the Commercialization and Legacy Committee. Meetings will typically take place either in person, or by teleconference, as determined by the Chair, and shall be called at least three (3) times per year. The Commercialization and Legacy Committee shall keep minutes of all meetings and report back to the Board at the next meeting.

8. Quorum

Quorum shall be a majority of its voting members present at the meeting, in person or by telephone.

9. Reporting

The Chair of the Commercialization and Legacy Committee shall report at each meeting of the Board of Directors on all of its proceedings, if any, since the last meeting of the Board of Directors. Minutes of the meeting shall be submitted to the Board of Directors for informational purposes.

10. History

The Commercialization and Legacy Committee Terms of Reference was:
- Approved by the Board of Directors on October 27, 2015.
- Updated to reflect new membership on April 8, 2016.
- Revised to reflect Cycle II funding strategy and approved by the Board of Directors on March 3, 2020.
Appendix A: List of Members and Observers

Dr. John Holyoake (Chair)
Vice President, Investment Banking
Bloom Burton & Co.

Dr. Samuel Abraham
Strategic Advisor
Western Economic Diversification

Ms. Christine Charette
Managing Partner
Scientia Advisors

Dr. Digvir Jayas
Vice-President, Research
University of Manitoba

Dr. David Rabuka
President & CEO
Acrigen Biosciences

Dr. Stephanie White
Partner
Kirby IP Canada

Dr. Kaley Wilson
Director, Business Development
Quark Venture

Dr. Stewart Fast (NCE Observer, Non-Voting)
Senior Project Manager
Networks of Centres of Excellence

Dr. Elizabeth Nanak (Secretary, Observer, Non-Voting)
Chief Executive Officer
Canadian Glycomics Network